efaroxan
Sign in to saveEfaroxan is an α2-adrenergic receptor antagonist and antagonist of the imidazoline receptor.
Research
304 papers- Idazoxan and Efaroxan Potentiate the Endurance Performances and the Antioxidant Activity of Ephedrine in Rats.Medicina (Kaunas, Lithuania) · 2021
- Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.Movement disorders : official journal of the Movement Disorder Society · 1998
- Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats.The Journal of pharmacology and experimental therapeutics · 1995
- Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan.Diabetes · 2001
- Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell.British journal of pharmacology · 2002
via PubMed
~1 min read
Encyclopedic overview
4 sectionsContents
- Synthesis
- See also
- References
- External links
Efaroxan is an α2-adrenergic receptor antagonist and antagonist of the imidazoline receptor.
==Synthesis== thumb|center|500px|class=skin-invert-image|Synthesis (Cmp#13): Revised:
Excerpted from Wikipedia’s “efaroxan” article, available under the CC BY-SA 4.0 licence.